Growing Focus on Early Detection of Infectious Ailments and Major Progress in Diagnostic Techniques Are Fueling the Growth of the Pneumonia Diagnostics & Technologies Market During the Forecast Period 2023-2028

The Pneumonia Diagnostics & Technologies Market size is estimated to reach $3.8 billion by 2028, growing at a CAGR of 8.5% during the forecast period 2023-2028. The growth of the Pneumonia Diagnostics & Technologies Market is greatly fueled by the increasing focus on the early detection of infectious ailments and major progress in diagnostic techniques. Early diagnosis of pneumonia is critical for deciding the suitable treatment of the ailment, healing the ailment comprehensively and stopping it from threatening the life of the patient. Diagnostic tests and procedures for pneumonia may involve chest x-ray, blood tests and pulse oximetry. These are further fueling the growth of the Pneumonia Diagnostics & Technologies Industry, thereby contributing to the Pneumonia Diagnostics & Technologies Industry Outlook.  By type, pneumonia testing is segmented into analyzers and consumables. Immunodiagnostics indicates an in-vitro diagnostic technology that utilizes antigen-antibody reaction for the detection of infectious and chronic ailments. 

Pneumonia Diagnostics & Technologies Market Growth Drivers:

Surging Applications of Consumables and Analyzers in Pneumonia Testing:

Principal diagnostic tests and procedures to diagnose pneumonia involve chest X-rays, blood tests and pulse oximetry. Acquiring a chest x-ray involves the application of numerous x-ray consumables. Hematology analyzers are utilized extensively in patient and research settings to count and characterize blood cells for disease detection and monitoring. Basic analyzers convey a complete blood count (CBC) with a three-part differential white blood cell (WBC) count. Investigations involving pulse oximetry have been conducted, which recommend that in acutely infected nursing home patients, a reduction in oxygen saturation of >3% from baseline, as well as a single oxygen saturation of <94, should indicate pneumonia. The surging applications of consumables and analyzers in pneumonia testing are therefore driving the growth of the Pneumonia Diagnostics & Technologies Market.

For More Queries About "Pneumonia Diagnostics & Technologies Market" @ https://www.industryarc.com/support.php?id=17562

Towering Applications of Immunodiagnostics:

Immunodiagnostics of community-acquired pneumonia among children has been conducted. A total of 840 pleura I fluid effusion samples from children with clinical and laboratory diagnoses of acute bacterial pneumonia were measured by Dot-ELISA. This technique was standardized to detect polysaccharide capsular bacterial antigen in pleural fluid samples formerly treated with 0.1 M EDTA and dotted on nitrocellulose membrane strips. Pneumococcal omniserum and H. influenza* type b antiserum diluted 1:200 were working for the detection of S. pneumoniae and H. influenza* type b antigens, respectively. Dot-ELISA demonstrated relative indices of 0.913 for sensitivity and 0.552 for specificity and total positivity of 75.6 percent, 53.21 percent for S. pneumoniae and 2238 percent for H. influenzae. The growing applications of Immunodiagnostics are therefore propelling the growth of the Pneumonia Diagnostics & Technologies Industry, thereby contributing to the Pneumonia Diagnostics & Technologies Industry Outlook.

Acquisition:

In August 2022, Bio-Rad Laboratories, Inc. declared that it had secured an agreement to gain all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. This was performed for a total consideration of up to $170 million.

Pneumonia Diagnostics & Technologies Market: Competitive Landscape

Key companies holding major shares in the Pneumonia Diagnostics & Technologies Market are Becton, Dickinson and Company (BD), Affymetrix (Thermo Fisher Scientific), Bio-Rad Laboratories, Inc., Abbott Laboratories, F. Hoffmann-La Roche AG., GSK plc, bioMérieux SA, DiaSorin, Hologic, Inc. and Fujirebio.